Compare Sibanye Stillwater Ltd (SBSW) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sibanye Stillwater Ltd vs GeneDx Holdings Corp — how do they compare? Sibanye Stillwater Ltd trades at $13.14 (market cap $9.35B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: Sibanye Stillwater Ltd is far larger — about 3.7× GeneDx Holdings Corp's market cap, and Sibanye Stillwater Ltd pays a 6.27% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| SBSW | WGS | |
|---|---|---|
Market Cap | $9.35B | $2.56B |
Sector | Basic Materials | Technology |
52-Week High | $21.12 | $167.51 |
52-Week Low | $8.00 | $34.51 |
Enterprise Value | $10.29B | $2.60B |
Dividend Yield | 6.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SBSW trades at $12.90, up 0.86% today, with a bullish technical signal from moving averages and ADX indicators. Recent Q2 2026 earnings beat expectations with EPS of $1.34 versus $1.26, and the company reported a strong turnaround in operating cash flow to $21.41 billion in 2025. Valuation ratios appear attractive with a P/E of 10.2 and EV/EBITDA of 5.2, while analyst consensus is a Buy with a $14.00 price target.
The outlook is positive due to robust earnings performance and improving cash flows, but risks include volatile commodity prices and high debt levels. Investment opportunity lies in potential upside to the consensus target, supported by operational momentum and disciplined capital allocation plans highlighted in recent news.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
